Erschienen in:
01.11.2015 | Rhinology
Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis
verfasst von:
Cemal Cingi, Nuray Bayar Muluk, Seçkin Ulusoy, Mustafa Acar, Seher Şirin, Bengü Çobanoğlu, Leman Birdane, Çiğdem Kalaycık, Burak Ömür Çakır, Fatih Oğhan, Sevilay Aynacı, Nagehan Erdoğmuş, Ömürsen Yıldırım, Ethem Şahin, Fuat Bulut, Mehmet Akif Aksoy, Nurullah Türe, Cengiz Bal
Erschienen in:
European Archives of Oto-Rhino-Laryngology
|
Ausgabe 11/2015
Einloggen, um Zugang zu erhalten
Abstract
In the present study, we investigated the outcomes of sublingual immunotherapy (SLIT) in house dust mite-induced allergic rhinitis (HDM-AR) patients. In this prospective, multicentric study, 186 patients with AR who had positive skin prick test results for HDMs were included. The patients were administered SLIT using Staloral 300 for 1 year. Evaluation of the patients regarding symptom scores, clinical findings and Rhinitis Quality of Life Questionnaire (RQLQ) scores was performed at baseline, and then at 6 and 12 months of therapy. Our results showed that, for all of the evaluated items (symptom scores, clinical findings and RQLQ scores), 12-month values were significantly lower than those at 6 months and baseline. Similarly, 6-month values were significantly lower than those at baseline. There were no complications in any of our patients. SLIT for HDM-AR is a treatment modality that can be used safely. We obtained better results than expected, and the treatment showed a positive psychological effect; the patients believed that SLIT was the final step of treatment and, which made them feel better.